Insight Molecular Diagnostics, Inc. (IMDX)
4.14
+0.13
(+3.24%)
USD |
NASDAQ |
Sep 22, 16:00
4.115
-0.02
(-0.60%)
After-Hours: 20:00
Insight Molecular Diagnostics Shareholders Equity (Quarterly) : -21.30M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.30M |
| March 31, 2026 | -10.69M |
| December 31, 2025 | -31.46M |
| September 30, 2025 | -9.196M |
| June 30, 2025 | 1.098M |
| March 31, 2025 | 10.22M |
| December 31, 2024 | -12.27M |
| September 30, 2024 | 9.711M |
| June 30, 2024 | 22.70M |
| March 31, 2024 | 16.92M |
| December 31, 2023 | 25.59M |
| September 30, 2023 | 42.48M |
| June 30, 2023 | 48.32M |
| March 31, 2023 | 43.46M |
| December 31, 2022 | |
| September 30, 2022 | 81.93M |
| June 30, 2022 | 88.10M |
| March 31, 2022 | 56.97M |
| December 31, 2021 | 65.22M |
| September 30, 2021 | 99.35M |
| June 30, 2021 | 102.67M |
| March 31, 2021 | 106.63M |
| Date | Value |
|---|---|
| December 31, 2020 | 33.48M |
| September 30, 2020 | 34.64M |
| June 30, 2020 | 39.59M |
| March 31, 2020 | 36.62M |
| December 31, 2019 | 30.84M |
| September 30, 2019 | 29.34M |
| June 30, 2019 | 33.50M |
| March 31, 2019 | 38.19M |
| December 31, 2018 | 3.423M |
| September 30, 2018 | 7.523M |
| June 30, 2018 | 6.846M |
| March 31, 2018 | 9.022M |
| December 31, 2017 | 4.403M |
| September 30, 2017 | 8.048M |
| June 30, 2017 | 5.639M |
| March 31, 2017 | 8.773M |
| December 31, 2016 | 9.862M |
| September 30, 2016 | 12.68M |
| June 30, 2016 | 4.467M |
| March 31, 2016 | 6.895M |
| December 31, 2015 | 10.42M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 323.86M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 29.44M |
| Total Liabilities (Quarterly) | 50.74M |
| Debt to Equity Ratio | -0.1232 |
| Current Ratio | 1.997 |
| Net Debt Paydown Yield | 0.09% |